Clinical Research Trial Outreach and Enrollment GrantThe V Foundation is interested in supporting the efforts of cancer centers to improve or expand their programs to increase outreach and recruitment for breast cancer clinical trials. Funds to support this grant were raised by regional franchisees of the Hooters of America, LLC. Corporation and donated to The V Foundation for Cancer Research to support programs at regional cancer centers for breast cancer clinical trial outreach.
A $44,000 one-year grant will support cancer centers in the following aims:
- Provide breast cancer clinical trial education programs
- Encourage diversity among participants
- Encourage multi-disciplinary involvement
- Raise accrual rates
Letter of Intent
Letters of Intent (not to exceed 2 pages) are due January 20, 2017 via email to firstname.lastname@example.org. Letters of Intent should include the PI’s NIH biosketch, a proposed title for the research project, and a brief description of the proposed research project. The selected investigator will be notified and invited to submit a full application due February 10, 2017.
Letter of Intent Deadline: January 20, 2017
Application Deadline: February 10, 2017
Contact: Jeff Mills, (404) 727-3634, email@example.com
Southeastern Brain Tumor Foundation Research Grants
The Southeastern Brain Tumor Foundation (SBTF) is a 501(c) 3 based in Atlanta. The SBTF funds translational research and investigator-initiated clinical trials focused on finding a cure for brain tumors. Since 2005, the SBTF has awarded over $2.3M in research grants. The foundation is interested in both pre-clinical studies and investigator-initiated clinical trials. The SBTF’s goal is to fund brain tumor research projects which are innovative and may ultimately be translated into clinically-viable therapies for patients diagnosed with a brain tumor. Up to $75,000 in funds may be distributed per proposal.
Grants are limited to pre-clinical research and clinical trials being conducted in the United States. The SBTF will not accept applications from a previous grant recipient who neglected to submit the required six-month and 12-month progress reports. Applications may be submitted by researchers at accredited public and private institutions, who hold full-time faculty appointments. “Research Associates” or individuals who hold an equivalent non-faculty level position are not eligible to apply.
Applicants must submit a grant application in PDF format to firstname.lastname@example.org. The application must be named as follows: first and last name of PI, institution name, grant year.
Application Deadline: midnight (EST) on Monday, January 30, 2017
Notification Date: April 30, 2017
PREVENT Cancer Preclinical Drug Development ProgramThe PREVENT Program was created in 2011 to provide investigators with novel ideas for interventions aimed at cancer prevention access to the National Cancer Institute’s (NCI) contract resources. Intervention strategies of high interest to PREVENT include chemoprevention and immunoprevention. Current areas of focus are:
- Anti-inflammatory approaches
- Novel mechanisms
- Drug repurposing
- Reducing toxicity (dosing and combinations)
The PREVENT Program application will not directly lead to a grant or contract award; rather NCI may allocate various contract resources and expertise towards implementation and development of approved, scientifically meritorious projects. Submission deadlines occur twice per year on the first Monday in February and September.
Application Deadline: February 6, 2017
ACSR Young Investigator Pilot Award
The AIDS and Cancer Specimen Resource (ACSR) is an NCI funded cooperative agreement that supports the collection and expert preservation of clinically-annotated biospecimens for multidisciplinary HIV research, bridging laboratory basic science with clinical, behavioral, and epidemiological studies. The ACSR Young Investigator Pilot Award is targeted toward junior investigators and faculty with innovative ideas for translational, clinical and/or behavioral-epidemiological HIV-related research that utilizes ACSR’s annotated biospecimens collected from HIV/AIDS patients and controls from both pre and post-HAART periods. Awards are intended for pilot studies to show feasibility and/or to generate preliminary data that will support efforts to procure future funding of larger research projects.
Completed applications should be submitted as PDF documents to CODCC@acsr.ucsf.edu.
Application Deadline: 5pm PDT, February 17, 2017
Winship is pleased to announce the third round of funding opportunities in the Winship Invest$ program, a peer-reviewed program designed to provide pilot funding for novel, innovative cancer research projects. Winship Invest$ will support pilot projects and enable Winship investigators to obtain preliminary data and results for publication and for peer-reviewed funding applications. Winship Invest$ will have two funding opportunities every year. Funded applications will be supported by philanthropic contributions to Winship and by developmental funds in Winship's Cancer Center Support Grant (CCSG). Proposals with a budget of up to $50,000 for one year may be considered for Winship Invest$ (unless otherwise stated for specific research domains).
Research Domains (see RFP for complete details)
Investigators may submit only one proposal per Winship Invest$ Request for Pilot Grant Proposals (RFP) cycle and identify within which research domain they seek consideration. The current Winship Invests RFP seeks applications in the following areas:
- Investigator Initiated Clinical Trials
- Immunology and Immunotherapy
- Integrative Cancer Imaging
- Pediatric Cancers
- Cancer Disease Type-Specific Research in: (a) breast cancer or (b) lung cancer
Letter of Intent and Application Process
Letters of Intent (not to exceed 2 pages) are due December 9 via email to email@example.com. Letters of Intent should identify the PI, all potential collaborators on the project, the research domain for which the project is to be considered, a proposed title for the research project, and a brief description of the proposed research project. Selected investigators will be notified and invited to submit a full application due February 1, 2017.
Letter of Intent Deadline: December 9, 2016
Application Deadline: February 1, 2017
Anticipated Start Date: April 1, 2017
Contact: Jeff Mills, (404) 727-3634, firstname.lastname@example.org
Pancreatic Cancer Research Grants
The Pancreatic Cancer Action Network is now accepting applications for its 2017 funding opportunities.
Precision Medicine Targeted Grant
Amount: Up to $1,000,000
Duration: Up to two years
Funding available for projects that can be incorporated directly into the Pancreatic Cancer Action Network’s Precision Promise initiative at the end of the funding period.
Application Deadline: Noon EST, February 15, 2017
Early Detection Targeted Grant
Amount: Up to $1,000,000 in milestone-driven units of $250,000
Duration: Up to four years
Supports studies to utilize a cohort of new onset diabetics with high risk of sporadic pancreatic cancer; projects
Application Deadline: Noon EST, February 22, 2017
KRAS Travel Scholarship
(in partnership with the NCI Frederick National Laboratory for Cancer Research)
Provides travel support to a researcher at any career stage, during or after the postdoctoral level, to visit FNLCR to pursue KRAS research that is directly relevant to pancreatic cancer with aims aligned with the RAS Initiative
Amount: Depending on need
Application Deadline: Rolling
Aplastic Anemia and MDS International Foundation Grants
For more than 20 years, the Aplastic Anemia and MDS International Foundation (AAMDISF) has provided investigators with financial support for research that leads to new insights into the causes of bone marrow failure and the development of new therapeutic approaches. Successful grant applicants can be funded up to $60,000 for two years ($30,000 each year, with second-year funding pending approved progress in the first year). Detailed criteria and applications instructions are available at https://proposalcentral.altum.com.
To be eligible to apply for a research grant, an applicant must hold a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Science, or other doctoral level degree (e.g., PharmD). There are no nationality restrictions. The project must represent independent research conducted by the applicant.
Grants can be awarded to new investigators and established Investigators. New investigators are post-doctoral fellows, instructors and those who have been assistant professors for fewer than five (5) years. Established Investigators have been assistant professors for five (5) years or more or are associate or full professors. Preference will be given to applications submitted by new investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research.
Topic areas considered for funding include:
- Promoting understanding of the etiology and pathogenesis of aplastic anemia, MDS or PNH;
- Improving symptom management and the quality of life for aplastic anemia, MDS or PNH patients;
- Discovering new treatments for aplastic anemia, MDS or PNH;
- Understanding and preventing complications of bone marrow failure conditions (e.g., blood clotting/thrombosis in PNH, iron overload in MDS, etc.); and,
- Research regarding inherited bone marrow failure disorders, provided a strong case is also made for pertinence of the research to acquired disorders.
In addition, the following criteria will be considered by reviewers:
- The likelihood that the goals of the proposal are attainable with the funding from AAMDSIF;
- The project is independent research and not part of a large, multi-funded study;
- The translational nature of the research and whether the findings can be rapidly applied to benefit patients; and,
- For new investigators, the likelihood that the project will contribute toward the professional development of the researcher.
- Applications that do not fall within the selection criteria, or that address a disease outside of our scope (e.g., acute leukemia), will be disqualified.
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents. Specifically, this program announcement encourages research grant applications to:
- Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence;
- Identify structural, systemic, and psychosocial barriers to adherence; and
- Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.